Omrix Biopharmaceuticals has announced that patient enrollment in the multicenter, Phase III pivotal trial for the company's Thrombin stand-alone product candidate has been completed.

Omrix's Thrombin stand-alone, which is derived from human plasma, is designed to provide effective hemostasis (control of bleeding) without the risk of adverse reactions associated with the use of bovine-sourced hemostats. The drug will be available in a frozen liquid form making it ready for immediate use without the need for re-constitution. While the product will have a two-year stability, it can be stored liquid in the operating room refrigerator for 30 days.